Retatrutide: the triple agonist that's rewriting the weight-loss playbook.

What Is Retatrutide?

Retatrutide — developer code LY3437943 — is an investigational, once-weekly, injectable peptide medication being developed by Eli Lilly and Company for chronic weight management, type 2 diabetes, metabolic dysfunction–associated steatohepatitis (MASH), obstructive sleep apnea, obesity-related knee osteoarthritis, and, in a separate program, Parkinson's disease. It is not yet approved by the FDA or any other regulator. That matters a lot and we'll come back to it.

What makes retatrutide unusual — and what has the obesity-medicine community paying attention — is its mechanism. Retatrutide is a triple agonist. A single molecule activates three separate hormone receptors at the same time:

• GLP-1 receptor — the same target as semaglutide (Ozempic, Wegovy).
• GIP receptor — the second target that tirzepatide (Mounjaro, Zepbound) added.
• Glucagon receptor — new territory for an approved or near-approved obesity drug.

Semaglutide is a single agonist. Tirzepatide is a dual agonist. Retatrutide is a triple agonist — sometimes informally described in patient communities as "GLP-3." That term isn't official pharmacology, but it captures the idea: each new generation of incretin therapy has added a receptor and produced more weight loss.

Retatrutide at a glance

How Retatrutide Works: the mechanism of action

The question "how does retatrutide work" has a short answer and a long one. The short version: it silences hunger and speeds up metabolism at the same time. The long version is more interesting, because it explains why three receptors beat one.

GLP-1: the appetite brake

Glucagon-like peptide-1 is released by the gut in response to food. Its effects in the context of incretin pharmacology are well-mapped: slower gastric emptying, greater satiety, improved glucose-dependent insulin secretion, and central appetite suppression via the hindbrain and hypothalamus. Activating GLP-1 alone produces the appetite-killing effect that made semaglutide a billion-dollar drug.

GIP: insulin sensitivity and fat handling

Glucose-dependent insulinotropic polypeptide does a different job. In tandem with GLP-1, GIP activation improves insulin sensitivity, promotes lipid storage in subcutaneous rather than visceral depots, and may reduce the nausea typical of pure GLP-1 activation. Tirzepatide — which adds GIP agonism to GLP-1 — produced larger weight loss than semaglutide in head-to-head cross-trial analysis.

Glucagon: the calorie burner

This is the receptor that makes retatrutide distinct. Glucagon is usually thought of as a "raise-blood-sugar" hormone, but at the pharmacological doses achieved by modern agonists, glucagon receptor activation increases energy expenditure, enhances lipolysis (fat breakdown in the liver), and reduces hepatic steatosis. Balancing this against GLP-1/GIP's glucose-lowering effects is the engineering trick that took years of medicinal chemistry to get right. On a pure GLP-1/GIP background, adding glucagon would raise blood sugar. When balanced correctly, it adds fat-loss metabolic horsepower without breaking glucose control.

Put another way: GLP-1 reduces intake, GIP improves metabolic handling, and glucagon increases output. Triple agonism hits the energy balance equation from three directions simultaneously.

Does retatrutide burn fat?

Effectively, yes. The glucagon component increases resting energy expenditure and hepatic fat oxidation, which means the body burns more energy at rest and preferentially uses fat stores. Combined with the appetite suppression from GLP-1/GIP, the net effect in Phase 2 trials was fat-mass-dominant weight loss. DEXA scans in a TRIUMPH-1 substudy showed that about 82% of weight lost was fat mass.

Clinical Data: What Phase 2 Actually Showed

Retatrutide's landmark Phase 2 trial, TRIUMPH-1, was published in the New England Journal of Medicine on July 27, 2023. It enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus a weight-related comorbidity, and randomized them to placebo or 1, 4, 8, or 12 mg of retatrutide weekly. Treatment lasted 48 weeks with a dose-escalation schedule starting at 0.5 mg.

The mean body-weight reduction at 48 weeks, from a mean baseline weight of ~108 kg:

A few details worth highlighting. First, the weight-loss curve at 48 weeks had not plateaued — participants on higher doses were still losing weight when the trial ended. This suggests peak efficacy beyond 48 weeks, consistent with what's being evaluated in the longer Phase 3 studies. Second, cardiometabolic markers moved in favorable directions across the board: systolic blood pressure dropped ~8 mmHg in the 12 mg arm, LDL cholesterol fell ~15%, and A1C dropped ~0.8 percentage points in the cohort with pre-diabetes.

TRIUMPH-2, a separate Phase 2 trial in adults with type 2 diabetes, reported A1C reductions of up to 2.0 percentage points plus 16.9% weight loss at 36 weeks — a remarkable combination, since many diabetes drugs trade glycemic control for weight gain or weight stasis.

Retatrutide Benefits — beyond the scale

The retatrutide weight-loss numbers are the headline. But the retatrutide benefits extend further, and that's why Lilly has launched separate Phase 3 programs in multiple indications:

• Cardiovascular risk reduction. Improvements in blood pressure, triglycerides, LDL, and waist circumference suggest meaningful reduction in atherosclerotic cardiovascular disease risk. TRIUMPH-3 is the dedicated cardiovascular outcomes trial.
• Metabolic dysfunction–associated steatohepatitis (MASH). The glucagon component specifically reduces hepatic fat, and early imaging data show substantial liver-fat reductions — a field currently dominated by resmetirom.
• Osteoarthritis (knee). Weight reduction mechanically offloads the knee joint. TRIUMPH-4 tests whether retatrutide-driven weight loss translates to reduced knee pain and improved function in osteoarthritis patients.
• Obstructive sleep apnea (OSA). Body-weight reduction is the single most effective treatment for most OSA. Retatrutide is being evaluated as a non-CPAP option.
• Parkinson's disease. A small trial is testing whether the GIP/glucagon-driven neurometabolic effects slow motor-symptom progression.
• Adolescent obesity. TRIUMPH-5 evaluates safety and efficacy in adolescents with obesity.

Is Retatrutide FDA Approved?

No — not as of 2026. Retatrutide has not been approved by the FDA, EMA, or any other regulatory agency for any indication. It is an investigational medication still completing Phase 3 trials. Pharmacies cannot legally dispense retatrutide; it is not a commercially available prescription drug.

Here's where the retatrutide FDA approval timeline stands today:

For a page we update as new data drops, see the retatrutide FDA approval status tracker.

Retatrutide vs Tirzepatide, Semaglutide, and the Rest

How does retatrutide stack up against the GLP-1/GIP drugs already on pharmacy shelves? Short answer: in Phase 2 cross-trial comparison, retatrutide edged out tirzepatide on average weight loss and significantly out-performed semaglutide. But cross-trial comparisons are imprecise, populations differ, and Phase 3 is where final efficacy gets settled.

Retatrutide Side Effects and Safety Signal

In TRIUMPH-1, the retatrutide side-effect profile was dose-dependent and largely gastrointestinal — consistent with the GLP-1/GIP class:

• Nausea — ~35–55% of participants on the higher dose arms during titration, mostly mild-to-moderate, declining with continued dosing.
• Diarrhea — ~20–30%.
• Constipation — ~15%.
• Vomiting — ~10–20%, higher on the 12 mg dose.
• Mild transient heart-rate increase — ~3–8 bpm on average, similar to other incretins.
• Small hyperglycemia signal at the highest dose in non-diabetics — consistent with the glucagon component pushing glucose slightly up, offset in Phase 3 by dose titration.

Serious adverse events were rare. There were no new safety signals relative to the GLP-1/GIP class. Hair loss, commonly cited by patient communities for semaglutide and tirzepatide, was reported in small percentages of participants on the higher retatrutide doses (likely related to rapid weight loss rather than the drug itself). Full breakdown: retatrutide side effects.

How to Get Retatrutide

The honest answer: you can't get it from a pharmacy, because it's not approved yet. People looking for retatrutide today generally find three options, each with a big caveat:

1. Clinical trials. If you qualify, you may be able to enroll in one of the ongoing Phase 3 studies. Listings are at ClinicalTrials.gov — search the NCT numbers on our FDA status page.
2. "Research peptide" vendors. Vials labeled "for research purposes only" circulate online. These are not FDA-approved, not for human use, and routinely found to be under-dosed, contaminated, or mis-identified in independent testing. Details and risks: retatrutide peptide page.
3. Compounding pharmacies. A small number of compounding pharmacies have marketed "compounded retatrutide" in the wake of the semaglutide/tirzepatide shortages. The regulatory status is murky at best — retatrutide isn't on the FDA drug shortage list, it's simply not approved. See the availability page.

You Can't Get Retatrutide. Here's What You Can Get.

Retatrutide's trial numbers are impressive. It is also, for practical purposes, 1–2 years away from your neighborhood pharmacy. That's a long time to sit and wait if you have 60 pounds to lose.

Here's the part most retatrutide coverage glosses over: FDA-approved GLP-1 medications with proven results are available to you right now. Not through your insurance necessarily — through direct-pay telehealth, which has re-priced this entire category. Semaglutide and tirzepatide programs start around $179/month. Medication included. Delivered to your door. No waiting rooms.

The average weight loss on tirzepatide in the SURMOUNT trials was 22.5%. The average weight loss on retatrutide 12 mg in Phase 2 was 24.2%. One point seven percentage points is not a reason to wait two years.

Frequently Asked Questions